Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 20/20 | 1.00 |
| ▸ | PKLR | P30613 | 18/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719967 | 0.96 | PKM (1.00) | PKMPKLRNPC1RAB9A | |
| SCHEMBL1722746 | 0.95 | PKM (1.00) | PKMPKLRNPC1RAB9A | |
| SCHEMBL1723099 | 0.90 | PKM (1.00) | PKMPKLRNPC1RAB9A | |
| SCHEMBL1726497 | 0.82 | PKM (1.00) | PKMPKLRNPC1RAB9A | |
| SCHEMBL1711005 | 0.82 | PKM (1.00) | PKMPKLRNPC1RAB9A | |
| SCHEMBL1722896 | 0.82 | PKM (1.00) | PKMPKLRNPC1RAB9A | |
| SCHEMBL12354651 | 0.82 | PKM (1.00) | PKMPKLRNPC1RAB9A | |
| SCHEMBL1726503 | 0.81 | PKM (1.00) | PKMPKLRNPC1RAB9A | |
| SCHEMBL1711253 | 0.81 | PKLR (1.00) | PKMPKLR | |
| SCHEMBL1722816 | 0.81 | PKM (1.00) | PKMPKLRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372230-B1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3372230-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | Agios Pharmaceuticals, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2704719-B1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS INC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9707230-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3173415-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2344453-B1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9403792-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160199370-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2016-07-14 | — | — | US | disclosed |
| US-9290512-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150105395-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2015-04-16 | — | — | US | disclosed |
| US-8937067-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-01-20 | — | — | US | disclosed |
| US-8841305-B2 | Activators of the human pyruvate kinase M2 receptor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-29 | — | — | US | disclosed |
| EP-2704719-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | Agios Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151450-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US Dept. of Health and Human Services (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105395-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 6/4885NPC1 4746/4885 |
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | PCK1, PDK2, PCK2 | PKM 14/4885PKLR 26/4885NPC1 3312/4885 |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 5/4885PKLR 7/4885NPC1 4729/4885 |
| US-20160199370-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 7/4885NPC1 4734/4885 |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 7/4885NPC1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.